FDA approves Lilly's ramucirumab

FDA approved Cyramza ramucirumab from Eli Lilly and Co. (NYSE:LLY) as monotherapy for advanced stomach cancer or gastroesophageal junction adenocarcinoma after prior fluoropyrimidine- or platinum-cont...